Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CASTLE BIOSCIENCES INCCSTL · Entity 359 | Chief Financial Officer | August 14, 2026 | August 18, 2026 |
| EXAGEN INC.XGN · Entity 935 | Director | June 09, 2026 | June 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CASTLE BIOSCIENCES INC
Report date August 14, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 35,177 |
Reported balance
After 2026-08-14 transaction · row 1
1 source rowRow 1 · 2026-08-14 · Sale · Disposed 24,908 · Balance 35,177 F1: This transaction was executed in multiple trades at prices ranging from $29.71 to $29.97, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades at prices ranging from $29.71 to $29.97, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
EXAGEN INC.
Report date June 09, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option(right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.31 · Expires 2036-06-08 | Direct | 112,500 |
Reported balance
After 2026-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 37,500 · Balance 112,500 F1: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The entire number of shares subject to this option becomes fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 03, 2020 Filed Dec 4, 2020 21:13 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionStock option (right to buy) · Derivative | 2,000 | $0.00 Strike: $3.38 | $0.00 |
DisclosureSEC source: 0001447362-20-000272 · wf-form4_160711641161876.xml · derivative · entry 2 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,712 Underlying: Common Stock · 2,000 shares Expires 2029-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the 28,712 shares originally subject to the option vested on March 13, 2020, and the remaining shares shall vest in 36 equal monthly installments thereafter. Read SEC document |
| December 03, 2020 Filed Dec 4, 2020 21:13 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionCommon Stock | 2,000 | $3.38 | $6,760.00 |
DisclosureSEC source: 0001447362-20-000272 · wf-form4_160711641161876.xml · nonDerivative · entry 1 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,886 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 13, 2020 Filed Nov 16, 2020 21:14 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionStock option (right to buy) · Derivative | 13,000 | $0.00 Strike: $2.39 | $0.00 |
DisclosureSEC source: 0001447362-20-000261 · wf-form4_160556126671585.xml · derivative · entry 11 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,137 Underlying: Common Stock · 13,000 shares Expires 2028-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020. F8 · derivative.exercise_date: The option is exercisable immediately, in whole or in part, conditioned upon the Reporting Person entering into a restricted stock purchase agreement with respect to any unvested shares. 25% of the 133,137 shares originally subject to the option vested on December 4, 2018, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| November 13, 2020 Filed Nov 16, 2020 21:14 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 200 | $52.04 | $10,408.00 |
DisclosureSEC source: 0001447362-20-000261 · wf-form4_160556126671585.xml · nonDerivative · entry 9 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,886 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020. F7 · price: This transaction was executed in multiple trades at prices ranging from $52.010 to $52.070, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 13, 2020 Filed Nov 16, 2020 21:14 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 633 | $51.30 | $32,474.17 |
DisclosureSEC source: 0001447362-20-000261 · wf-form4_160556126671585.xml · nonDerivative · entry 8 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,086 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020. F6 · price: This transaction was executed in multiple trades at prices ranging from $51.000 to $51.800, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 13, 2020 Filed Nov 16, 2020 21:14 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 12,167 | $50.41 | $613,301.97 |
DisclosureSEC source: 0001447362-20-000261 · wf-form4_160556126671585.xml · nonDerivative · entry 7 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,719 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $50.000 to $50.885, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 13, 2020 Filed Nov 16, 2020 21:14 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionCommon Stock | 13,000 | $2.39 | $31,070.00 |
DisclosureSEC source: 0001447362-20-000261 · wf-form4_160556126671585.xml · nonDerivative · entry 6 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,886 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020. Read SEC document |
| November 12, 2020 Filed Nov 16, 2020 21:14 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionStock option (right to buy) · Derivative | 13,000 | $0.00 Strike: $2.39 | $0.00 |
DisclosureSEC source: 0001447362-20-000261 · wf-form4_160556126671585.xml · derivative · entry 10 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,137 Underlying: Common Stock · 13,000 shares Expires 2028-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020. F8 · derivative.exercise_date: The option is exercisable immediately, in whole or in part, conditioned upon the Reporting Person entering into a restricted stock purchase agreement with respect to any unvested shares. 25% of the 133,137 shares originally subject to the option vested on December 4, 2018, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| November 12, 2020 Filed Nov 16, 2020 21:14 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 69 | $52.96 | $3,654.24 |
DisclosureSEC source: 0001447362-20-000261 · wf-form4_160556126671585.xml · nonDerivative · entry 5 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,886 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020. Read SEC document |
| November 12, 2020 Filed Nov 16, 2020 21:14 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 5,731 | $52.20 | $299,163.93 |
DisclosureSEC source: 0001447362-20-000261 · wf-form4_160556126671585.xml · nonDerivative · entry 4 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,955 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $51.770 to $52.675, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 12, 2020 Filed Nov 16, 2020 21:14 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 2,121 | $51.19 | $108,573.99 |
DisclosureSEC source: 0001447362-20-000261 · wf-form4_160556126671585.xml · nonDerivative · entry 3 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,686 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $50.630 to $51.585, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 12, 2020 Filed Nov 16, 2020 21:14 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 5,079 | $50.20 | $254,970.88 |
DisclosureSEC source: 0001447362-20-000261 · wf-form4_160556126671585.xml · nonDerivative · entry 2 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,807 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $49.585 to $50.560, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 12, 2020 Filed Nov 16, 2020 21:14 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionCommon Stock | 13,000 | $2.39 | $31,070.00 |
DisclosureSEC source: 0001447362-20-000261 · wf-form4_160556126671585.xml · nonDerivative · entry 1 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,886 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020. Read SEC document |
| October 14, 2020 Filed Oct 15, 2020 20:20 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionStock option (right to buy) · Derivative | 13,000 | $0.00 Strike: $2.39 | $0.00 |
DisclosureSEC source: 0001447362-20-000241 · wf-form4_160279320126025.xml · derivative · entry 8 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,137 Underlying: Common Stock · 13,000 shares Expires 2028-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020. F6 · derivative.exercise_date: The option is exercisable immediately, in whole or in part, conditioned upon the Reporting Person entering into a restricted stock purchase agreement with respect to any unvested shares. 25% of the 133,137 shares originally subject to the option vested on December 4, 2018, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| October 14, 2020 Filed Oct 15, 2020 20:20 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 1,300 | $55.13 | $71,674.20 |
DisclosureSEC source: 0001447362-20-000241 · wf-form4_160279320126025.xml · nonDerivative · entry 6 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,886 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $55.115 to $55.140, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 14, 2020 Filed Oct 15, 2020 20:20 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 8,300 | $54.58 | $453,014.00 |
DisclosureSEC source: 0001447362-20-000241 · wf-form4_160279320126025.xml · nonDerivative · entry 5 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,186 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $54.105 to $55.100, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 14, 2020 Filed Oct 15, 2020 20:20 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 3,400 | $53.06 | $180,417.60 |
DisclosureSEC source: 0001447362-20-000241 · wf-form4_160279320126025.xml · nonDerivative · entry 4 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,486 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $52.810 to $53.780, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 14, 2020 Filed Oct 15, 2020 20:20 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionCommon Stock | 13,000 | $2.39 | $31,070.00 |
DisclosureSEC source: 0001447362-20-000241 · wf-form4_160279320126025.xml · nonDerivative · entry 3 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,886 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020. Read SEC document |
| October 13, 2020 Filed Oct 15, 2020 20:20 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionStock option (right to buy) · Derivative | 13,000 | $0.00 Strike: $2.39 | $0.00 |
DisclosureSEC source: 0001447362-20-000241 · wf-form4_160279320126025.xml · derivative · entry 7 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,137 Underlying: Common Stock · 13,000 shares Expires 2028-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020. F6 · derivative.exercise_date: The option is exercisable immediately, in whole or in part, conditioned upon the Reporting Person entering into a restricted stock purchase agreement with respect to any unvested shares. 25% of the 133,137 shares originally subject to the option vested on December 4, 2018, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| October 13, 2020 Filed Oct 15, 2020 20:20 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 13,000 | $54.79 | $712,283.00 |
DisclosureSEC source: 0001447362-20-000241 · wf-form4_160279320126025.xml · nonDerivative · entry 2 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,886 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $54.280 to $55.200, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 13, 2020 Filed Oct 15, 2020 20:20 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionCommon Stock | 13,000 | $2.39 | $31,070.00 |
DisclosureSEC source: 0001447362-20-000241 · wf-form4_160279320126025.xml · nonDerivative · entry 1 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,886 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020. Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 20:05 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionStock option (right to buy) · Derivative | 13,000 | $0.00 Strike: $2.39 | $0.00 |
DisclosureSEC source: 0001447362-20-000221 · wf-form4_160028671746913.xml · derivative · entry 7 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,137 Underlying: Common Stock · 13,000 shares Expires 2028-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020. F6 · derivative.exercise_date: The option is exercisable immediately, in whole or in part, conditioned upon the Reporting Person entering into a restricted stock purchase agreement with respect to any unvested shares. 25% of the 133,137 shares originally subject to the option vested on December 4, 2018, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 20:05 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 7,741 | $49.43 | $382,606.67 |
DisclosureSEC source: 0001447362-20-000221 · wf-form4_160028671746913.xml · nonDerivative · entry 5 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,886 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $49.160 to $50.000, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 20:05 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 5,259 | $48.52 | $255,145.64 |
DisclosureSEC source: 0001447362-20-000221 · wf-form4_160028671746913.xml · nonDerivative · entry 4 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,627 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $48.145 to $49.120, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 20:05 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionCommon Stock | 13,000 | $2.39 | $31,070.00 |
DisclosureSEC source: 0001447362-20-000221 · wf-form4_160028671746913.xml · nonDerivative · entry 3 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,886 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020. Read SEC document |
| September 14, 2020 Filed Sep 16, 2020 20:05 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionStock option (right to buy) · Derivative | 13,000 | $0.00 Strike: $2.39 | $0.00 |
DisclosureSEC source: 0001447362-20-000221 · wf-form4_160028671746913.xml · derivative · entry 6 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,137 Underlying: Common Stock · 13,000 shares Expires 2028-05-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020. F6 · derivative.exercise_date: The option is exercisable immediately, in whole or in part, conditioned upon the Reporting Person entering into a restricted stock purchase agreement with respect to any unvested shares. 25% of the 133,137 shares originally subject to the option vested on December 4, 2018, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| September 14, 2020 Filed Sep 16, 2020 20:05 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | SaleCommon Stock | 13,000 | $49.98 | $649,779.00 |
DisclosureSEC source: 0001447362-20-000221 · wf-form4_160028671746913.xml · nonDerivative · entry 2 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,886 F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $49.410 to $50.170, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 14, 2020 Filed Sep 16, 2020 20:05 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | Exercise / conversionCommon Stock | 13,000 | $2.39 | $31,070.00 |
DisclosureSEC source: 0001447362-20-000221 · wf-form4_160028671746913.xml · nonDerivative · entry 1 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,886 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on August 12, 2020. F2 · balance_after: Includes 826 shares and 1,060 shares acquired on February 28, 2020 and August 31, 2020, respectively, under the Issuer's employee stock purchase plan. Read SEC document |
| December 13, 2019 Filed Dec 17, 2019 21:13 UTC | CASTLE BIOSCIENCES INC CSTL · Entity 359 | GrantStock option (right to buy) · Derivative | 55,000 | $0.00 Strike: $29.50 | $0.00 |
DisclosureSEC source: 0001447362-19-000026 · wf-form4_157661719990981.xml · derivative · entry 1 Stokes Frank · CIK 0001782815 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2020-12-12 F1 · derivative.exercise_date: 25% of the shares shall vest on December 13, 2020, and the remaining shares shall vest in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.